one of the things that jumps out is that at the current cash burn rate, their money lasts well into 2008, and that's without any further expense reductions.
Four noted topics in press release:
-- The results of the Company's recent research study in which improvements to its technology demonstrated sensitivity in stool in excess of 80% for detecting colorectal cancer [nice to see them sticking with this, hopefully the science is as sound as their stated conviction on this]
-- Quarterly accession growth [sounds like they are projecting sales growth, that would be nice, if they are, hope there is some evidence]
-- 2006 focus [pretty much no what that is, would be nice to hear of some progress with acs and cms, at least whether there is any clarity about what needs to be accomplished, a check list of sorts]
-- Regulatory update. [hopefully no bombs]
No predictions here other than I think there is more likely than not that there is little negative, though there might be little immediately viewed as positive.